Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sophiris Bio Inc SPHS

Healthcare Biotechnology
Sophiris Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of products for the treatment of urological diseases. The company's product portfolio includes topsalysin (PRX302), for the treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. Topsalysin is... see more

Recent & Breaking News (EXPM:SPHS)

Sophiris Bio to Present at the H.C. Wainwright 20th Annual Global Investment Conference

PR Newswire August 29, 2018

Sophiris Bio Updates on Phase 2b Localized Prostate Cancer Trial

PR Newswire August 29, 2018

Sophiris Bio Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

PR Newswire August 14, 2018

Sophiris Bio Reports Top-Line Interim Safety and Biopsy Findings For its Phase 2b Clinical Trial of Topsalysin in Localized Prostate Cancer

PR Newswire June 25, 2018

Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

Benzinga.com  May 16, 2018

Sophiris Bio Reports First Quarter 2018 Financial Results and Key Corporate Highlights

PR Newswire May 14, 2018

Sophiris Bio Announces Complete Enrollment in Phase 2b Topsalysin Study of Localized Prostate Cancer

PR Newswire December 11, 2017

Sophiris Bio to Participate in the 29th Annual Piper Jaffray Healthcare Conference

PR Newswire November 27, 2017

Sophiris Bio Reports Third Quarter Financial Results and Key Corporate Highlights

PR Newswire November 9, 2017

Sophiris Bio Provides Enrollment Update on Topsalysin Phase 2b Study in Localized Prostate Cancer

PR Newswire October 2, 2017

Sophiris Bio Secures up to $10 Million in Term Loans from Silicon Valley Bank

PR Newswire September 13, 2017

Sophiris Bio to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

PR Newswire August 17, 2017

Sophiris Bio Added to Russell Microcap Index

PR Newswire June 23, 2017

Sophiris Bio Announces that the First Patient Has Been Dosed in Phase 2b Study of Topsalysin in Patients with Clinically Significant Localized Prostate Cancer

PR Newswire June 8, 2017

Sophiris Bio Provides Update on Phase 2b Study of Topsalysin in Localized Prostate Cancer

PR Newswire May 23, 2017

Sophiris Bio Reports First Quarter Financial Results and Key Corporate Highlights

PR Newswire May 15, 2017

Sophiris Bio Presents Topsalysin Data from Phase 2a Proof-of-Concept Study in Localized Prostate Cancer at 112th American Urological Association (AUA) Meeting

PR Newswire May 15, 2017

Generic Drugs Stocks on Investors' Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio

PR Newswire April 7, 2017

Sophiris Bio to Present at 16th Annual Needham Healthcare Conference

PR Newswire March 29, 2017

Sophiris Bio Reports Fourth Quarter and Full Year 2016 Financial Results and Key Corporate Highlights

PR Newswire March 27, 2017